Loading clinical trials...
Loading clinical trials...
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction
Conditions
Interventions
CAP-1002 Allogeneic Cardiosphere-Derived Cells
Placebo
Locations
32
United States
Cardiology, P.C.
Birmingham, Alabama, United States
Heart Center Research
Huntsville, Alabama, United States
Scripps
La Jolla, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Florida - Shands Hospital
Gainesville, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
Start Date
November 13, 2012
Primary Completion Date
July 3, 2017
Completion Date
February 28, 2019
Last Updated
April 9, 2024
NCT07478003
NCT07142265
NCT06939738
NCT05168462
NCT04528511
NCT04973397
Lead Sponsor
Capricor Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions